Table 3 Clinical trials of exosome listed on ClinicalTrials.gov
Number | Principal Investigator | Sponsor | Disease | Phase | Patient number | Route of administration | Dose | Frequency, interval |
|---|---|---|---|---|---|---|---|---|
NCT05808400 | Jihui Du | Huazhong University of Science and Technology, China | chronic cough after COVID-19 | 1 | Exosome: 40, Control: 40 | iv | 1 × 109 particles/ml. × 5 ml | 5 days, twice daily |
NCT04356300 | Liang-Wan Chen | Fujian Medical University, China | Multiple organ dysfunction syndrome after surgical repair of acute type A aortic dissection | N/A | 60 | iv | 150Â mg | Once a day for 14Â days |
NCT05871463 | Behzad Hatami | Research Institute for Gastroenterology and Liver Diseases, Iran | Decompensated liver cirrhosis | 2 | 15 | iv | Final dose of 40Â mg | 3Â weeks |
NCT05413148 | Kuddusi Erkılıç | TC Erciyes University, Turkey | Retinitis | 2/3 | 135: MSC vs. exosome vs. placebo | Subtenon’s injection for single eye | Not described | One dose |
NCT05787288 | Xiaoying Huang | First Affiliated Hospital of Wenzhou Medical University, China | COVID-19 Pneumonia | early phase 1 | 240 (Nebulized extracellular vesicles (EV) vs. saline) | iv | 1 × 109 particles/ml × 5 ml | Twice a day for 5 days |
NCT05387278 | no information | Vitti Labs, LLC | Severe ARDS associated with COVID-19 | 1 | 20 (Exosome + MSC 10 vs. placebo 10) | iv | No information | No information |